West Virginia NP's Drug Rx Rights Yanked by Inaction
Published Date: 7/16/2025
Notice
Summary
Osric Malone Prioleau, a nurse practitioner from West Virginia, lost his DEA registration because he no longer has state permission to handle controlled substances. He didn’t ask for a hearing, so the DEA officially revoked his registration as of early 2025. This means he can’t legally prescribe or manage controlled drugs anymore, effective immediately.
Analyzed Economic Effects
2 provisions identified: 0 benefits, 2 costs, 0 mixed.
DEA Registration Revoked for Named Nurse
The Drug Enforcement Administration revoked DEA Certificate of Registration No. MM2233827 issued to Osric Malone Prioleau, N.P., and will deny any pending renewals or other registration applications in West Virginia. The Order is effective August 15, 2025; the record shows his West Virginia nursing licenses were suspended on August 22, 2024 and his DEA registration expired January 31, 2025. Mr. Prioleau may file a properly supported motion for reconsideration of the findings of fact within fifteen calendar days of the date of this Order.
DEA May Revoke When State License Suspended
The DEA states that it may suspend or revoke a practitioner's federal registration under 21 U.S.C. 824(a)(3) when the practitioner’s state license or registration has been suspended or revoked so the practitioner is no longer authorized to handle controlled substances under state law. The Agency also affirms it may adjudicate and enter final orders even where a DEA registration expired before the Order to Show Cause was issued.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-11526 — Implementation of the Substance Use-Disorder Prevention That Promotes Opioid Recovery and Treatment for Patients and Communities Act of 2018: Dispensing and Administering Controlled Substances for Medication-Assisted Treatment
Starting July 9, 2026, new rules make it easier for doctors and pharmacies to provide medicine that helps people recover from opioid addiction. These changes affect healthcare providers by expanding who can give medication-assisted treatment and how pharmacies can deliver these medicines. The goal? Faster, safer access to treatment with clear rules that save time and support recovery.
2026-10128 — Revision of Applications for Manufacturing and Procurement Quotas
The DEA wants to update how companies apply for permission to make and buy certain controlled drugs and chemicals. These changes will make the rules clearer, help prevent drug shortages, and ensure enough supply for medical and scientific needs. If you’re a manufacturer or involved in this process, get ready to follow new steps and share your thoughts by July 20, 2026.
2026-12140 — Importer of Controlled Substances Application: Scottsdale Research Institute
Scottsdale Research Institute wants to become an official importer of some controlled substances like ibogaine and marijuana. People who make or import these drugs can share their thoughts or ask for a hearing by July 17, 2026. This move could affect how these substances are brought into the U.S., but no costs or fees are mentioned yet.
2026-12144 — Importer of Controlled Substances Application: Wedgewood Pharmacy LLC
Wedgewood Pharmacy LLC wants to become an official importer of certain strong controlled substances, like Etorphine HCL and Thiafentanil. This affects drug manufacturers and others in the supply chain who can comment or request a hearing by July 17, 2026. No direct costs are mentioned, but the decision could impact how these drugs enter the U.S. market.
2026-12143 — Importer of Controlled Substances Application: AndersonBrecon, Inc. DBA PCI Pharma Services
AndersonBrecon, Inc. DBA PCI Pharma Services wants to become an official importer of certain controlled substances, including some strong drugs like tetrahydrocannabinols. People and companies involved with these drugs can share their thoughts or ask for a hearing by July 17, 2026. This move could impact how these substances are brought into the U.S., but no costs or fees were mentioned yet.
2026-11909 — Importer of Controlled Substances Application: Cerilliant Corporation
Cerilliant Corporation wants to become an official importer of certain controlled substances, including some drugs that need strict government oversight. People and companies involved with these substances can share their thoughts or ask for a hearing by July 15, 2026. This move could affect how these drugs enter the U.S. and might impact businesses handling them.
Previous / Next Documents
Previous: 2025-13315 — Benson Sergiles, P.A.; Decision and Order
Benson Sergiles, P.A., a medical practice in Arizona, lost its DEA registration because it no longer has the state permission to handle controlled substances. Despite multiple attempts, the DEA couldn’t reach them for a hearing, so the registration was revoked by default. This means Benson Sergiles can’t legally manage controlled drugs anymore, effective immediately, impacting their business operations.
Next: 2025-13318 — Revised Specification Pursuant to the Personal Responsibility and Work Opportunity Reconciliation Act of 1996
The Attorney General just updated a key rule from 2001 tied to the Personal Responsibility and Work Opportunity Act. This change affects agencies handling work and welfare programs, making sure the rules stay fresh and clear. No big money changes yet, but everyone should watch for new instructions soon.